2067 - Preclinical Characterization of Rationally Designed Microbial Consortia to Prevent Bacterial Infections in Patients with Chronic Liver Disease

Presenting Author(s)

• 

  Elizabeth Halvorsen, PhD

  Director
  Seres Therapeutics
  Cambridge, MA, United States

  Slides

Co-Author(s)

• MV

  Marin Vulić, PhD

  Senior Principal Scientist
  Seres Therapeutics
  Cambridge, Massachusetts, United States
• KB

  Kelsey Barrasso, PhD

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• NB

  Nicholas Beauchemin, n/a

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• JB

  Jessica Brown, n/a

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• NE

  Nathaniel J. Ennis, n/a

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• MM

  Melissa Mayol, n/a

  Seres Therapeutics
  Cambridge, Massachusetts, United States
• 

  Jenna I. Wurster, PhD (she/her/hers)

  Scientist, Computational Microbiome Sciences, Research & Development
  Seres Therapeutics
  Cambridge, Massachusetts, United States
• EO

  Edward J. O'Brien, PhD

  Group Leader, Computational Microbiome Sciences
  Seres Therapeutics
  Cambridge, Massachusetts, United States
• CF

  Christopher Ford, PhD

  Director
  Seres Therapeutics, Inc
  Cambridge, MA, United States
• MH

  Matthew Henn, PhD

  EVP, Cheif Scientific Officer
  Seres Therapeutics, Cambridge, MA
  Cambridge, Massachusetts, United States